PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Non-invasive diagnosis of bladder cancer with the BTA stat test
Article published in Urologia Polska 2004/57/1.

authors

Aleksandra Binka-Kowalska 1, Edyta Borkowska 1, Maria Constantinou 1, Ewa Zając 1, Agnieszka Nawrocka 2, Marcin Matych 3, Józef Matych 3, Bogdan Kałużewski 1
1 Zakład Genetyki Medycznej Uniwersytetu Medycznego w Łodzi
Kierownik zakładu: prof. dr hab. Bogdan Kałużewski
2 Zakład Patomorfologii Uniwersytetu Medycznego w Łodzi
Kierownik zakładu: prof. dr hab. Wielisław Papierz
3 Oddział Urologii i Trans

keywords

bladder, bladder cancer, BTA stat test, diagnosis, bladder cancer recurrences

summary

purpose
The aim of this study was to estimate the sensitivity of the BTA stat test in early, non-invasive diagnosis of bladder cancer and to evaluate the possible role of the BTA stat test in the detection of primary and recurrent bladder cancer.
material
Initially the study included 111 patients with signs or symptoms suggestive of bladder cancer and a past history of treated bladder cancer. Then, we excluded 35 patients: 21 with non-malignant urinary tract diseases (i.e. benign prostatic hyperplasia, cystitis) and 14 patients with primary and recurrent bladder tumour with gross hematuria or bacteriuria in the urine sample. Finally we examined 76 patients: 52 with primary bladder cancer, 16 with recurrent bladder cancer and 8 patients with a history of bladder cancer without tumour recurrence at the time of examination.
methods
Voided urine samples from patients were tested by the BTA stat test, immunochromatographic qualitative assay for detection of bladder tumour associated antigen (BTA).
results
The sensitivity of BTA stat test was 67% for the primary and 50% for the recurrent tumours. The BTA stat test was negative in 7 of 8 samples from patients with a history of bladder cancer without tumour recurrence at the time of routine follow-up cystoscopy.
conclusions
The BTA stat test is simple, rapid and inexpensive assay used in diagnosis of primary and recurrent bladder cancer. Usefulness of this test in detection of recurrence in patients being monitored for bladder cancer is limited because of low sensitivity of the BTA stat test in these cases. However, BTA stat test appears to be useful as a screening tool in high-risk patients (with primary tumours grades G2-G3), but it is necessary to consider a possibility of false positive results if patients have received intravesical instillation of BCG.

references

  1. Didkowska J. Wojciechowska U. Tarnowski W. Zatoński W: „Nowotwory złośliwe w Polsce w 1999 roku\\\". Centrum Onkologii - Instytut im. M. Sklodowskiej-Curic. Zakład Epidemiologii i Prewencji Nowotworów; 15-37.
  2. SzeSzenia-Dąbrowska N, Strzelecka A. Wilczyńska U. Szymczak W: Occupational malignant neoplasmas in Poland in the years 1971-1994: Medycyna Pracy XLVIII, 1997:1: 2-14.
  3. Knowles MA. What we could do now: molecular pathology of bladder cancer. J Clin Pathol: .Mol Pathol 2001; 54: 21 5-221.
  4. Szopiiiski T Chłosta P. Dzik T. Kata G. Antoniewicz AA, Borówka A: Ocena przydatności biopsji tru-cut do określenia stopnia zaawansowania raka pęcherza moczowego. Badanie doświadczalne. Uroi Pol 2003:1:50-55.
  5. Glas AS, RoosD, Deutekom M. Zwinderman All. Bossuyt PM, Kurth KII. Tumor markers in the diagnosis oj primary bladder cancer. A systematic review. J Urol 2003; 169 6:1975-1982.ft. Kinders R, Jones T. Root R. Bruce C, Murchison H, Corey M. Williams L, Enfield D. Hass GM. Complement factor Hora related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998: 4 (10): 2511-1520.
  6. Sharma S. Zippe CD. Pandrangi L. Nelson 1), Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999:162 (1): 53-57.
  7. , Lcyh H, Marberger M, Conort P, Sternberg C. Pansadoro V. Pagano,Bassi P, Boccon-Gibod L, Ravery V. Trciber U. Ishak L: Comparison of the BTA sUit test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999; 35 (1): 52-56.
  8. Pode D, Shapiro A, Wald M, Nativ O, Laufer M. Kavcr I. Noninvasive detection of bladder cancer witti the BTA stat test. J Urol 1999:161 (2): 443-446.
  9. Giannopoulos A. ManousakasT. Gounari A, Constantinidcs C, Cho-remi-Papadopoulou H, Dimopoulos C: Comparative evaluation of the diagnostic performance of the BTA stat test. NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001: 166 (2): 470-475.
  10. Gutierrez Banos JL, del Henar Rebollo Rodrigo M, Ailtolin Juarez
  11. FM, Garcia BM: Usefidness of the BTA STAT Test, for tlie diagnosis of bladder cancer. Urology 2001; 57 (4): 685-689.
  12. Raitanen MP. Hellstrom P. Marttila T. Korhonen H, Talja M, Ervasti J. Tammela XL: Fiunbladder Group. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) lest. Eur Urol 2001:40 (4): 422-426.
  13. Friedrich MG, Hellstern A. Haulmann SH. Graefen M, Conrad S, Hu-land E, Huland H: Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p.3/12 with the BTA STAT and NMP22 tests. J Urol 2002:168 (2): 470-474.
  14. Lipiński M, Jeromin L: Comparison of the bladder tumour antigen test with photodynamic diagnosis in patients with pathologically confirmed recurrent superficial urinary bladder tumours. BJU Lit 2002; 89 (7): 757-759.
  15. Boman H, Hedeliii H, Holmang S: Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002; 167 (1): 80-83.
  16. Raitanen ME Tammela \\\'PL: Specificity of human complement factor H-relatedprotein test (Bard BTA stat Test). Scand J Urol Nephrol 1999; 33 (4): 234-236.
  17. Heicappell R, Muller M, Fimmers R, Miller K: Qualitative determination of urinary human complement factor B-reMed protein (hcfHrp) in patients witli bladder cancer, healthy controls, and patients with benign urologie disease. Urol Int 2000; 65 (4): 181-184.
  18. Lokeshwar VB, Schroeder GL, Selzer MG, Haulmann SH, Posey JT. Duncan RC. Watson R, Rose L, Markowitz S. Soloway MS: Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyahtronidase and BTA-Stat tests. Cancer 2002; 95(1): 61-72.
  19. Raitanen MR Leppilahti M, Tuhkanen K. Forssel T, Nrylund P Tammela T: Tlie FinnBladder Group. Routine jbllow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer. Ann Chir Gynaecol 2001; 90 (4): 261-265.
  20. Raitanen MP Kaasinen E. Lukkarinen 0, Kauppinen R. Viitanen J, Liukkonen T, Tammela TL: Finnbladder Group. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer. Urology 2001; 57 (4): 680-684,
  21. Wald M, Halachmi S. Amiel G. Madjar S. Mullerad M, Miselevitz I, Moskovitz B. Nativ 0: Bladder tumor antigen stat test in non-ur-othelial malignant urologie conditions. Isr Med Assoc J 2002: 4(3): 174-175.
  22. Oge 0. Kozaci D. Gemalmaz H: Tlie BTA stat test is nonspecific for hematuria: an experimental hematuria model. J Urol 2002: 167 (3): 1318-1319.
  23. Quek P, Chin CM, Lim PH: The role of BTA stat in clinical practice. Ann Acad Med Singapore 2002: 31 (2): 212-216.

correspondence

Aleksandra Binka-Kowalska
Zakład Genetyki Medycznej
ul. Sterltnga l/1
91-425 Łódź